Ann: Extension Study Begins, Analysis Suggests Survival Benefit, page-39

Grainofsand, slide 12 of the same presentation states that the "Shortest time since diagnosis ~16 months compared to the longest ~49 months for the completed Phase 1 MEND Study". I think this detail, at least in part, addresses your point.

Also, if I recall correctly, MT mentioned in a Nov 23 presentation that most patients started Monepantel 24 months from being diagnosed and had been on the program 13 months at that stage - we are now at 16 months. This is incredibly exciting considering that Relyvrio only prolongs life by approx 12.5 months from 24 months since diagnosis (or 9 months from 27.5 months since diagnosis).